open access

Vol 67, No 8 (2009)
Other
Published online: 2009-09-09
Submitted: 2012-12-28
Get Citation

Original article
Factor XIII Val34Leu polymorphism as a modulator of fibrin clot permeability and resistance to lysis in patients with severe coronary artery disease

Ewa Stępień, Dariusz Plicner, Bogusław Kapelak, Ewa Wypasek, Jerzy Sadowski, Anetta Undas
Kardiol Pol 2009;67(8):947-955.

open access

Vol 67, No 8 (2009)
Other
Published online: 2009-09-09
Submitted: 2012-12-28

Abstract


Background: A common G to T transition in codon 34 with the subsequent valine with leucine replacement in the factor (F) XIII A-subunit affects fibrin formation and stabilisation in vitro. Data on the effects of Leu34 allele on cardiovascular thromboembolic events in vivo are conflicting.
Aim: We investigated whether FXIII Val34Leu polymorphism is potent enough to affect fibrin clot properties in patients with advanced coronary artery disease (CAD).
Methods: We studied 113 patients, aged 62.8 ± 6.1 years, who were scheduled for elective isolated coronary artery bypass grafting surgery (CABG). Patients were compared with 98 healthy age-matched controls. Ex vivo fibrin clot permeability and lysis time (t50%) were determined in citrated plasma.
Results: Patients scheduled for CABG had lower clot permeability (9.14 ± 1.64 vs. 10.02 ± 1.12 × 10-9 cm2; p = 0.0002) and longer t50% (8.45 ± 1.94 vs. 7.63 ± 1.24 min; p < 0.0001) than controls. The Leu34 carriers, i.e. 9 (8%) Leu34Leu homozygous and 23 (20%) Val34Leu heterozygous subjects, had lower permeability by 23% in the CAD group compared with 81 (72%) patients with Val34Val genotype. A similar intergroup difference was observed for t50% which was longer in Leu34 carriers (p < 0.0001). The FXIII Leu34 allele frequency in the control group was similar as well as the impact of Leu34 allele on fibrin properties. The effect of FXIII Leu34 allele on permeability and t50% was not affected by homocysteine, C-reactive protein and fibrinogen levels in CAD patients and controls.
Conclusions: Like in healthy subjects, in patients scheduled for CABG, the FXIII Leu34 allele is associated with decreased fibrin clot permeability and efficiency of lysis.

Abstract


Background: A common G to T transition in codon 34 with the subsequent valine with leucine replacement in the factor (F) XIII A-subunit affects fibrin formation and stabilisation in vitro. Data on the effects of Leu34 allele on cardiovascular thromboembolic events in vivo are conflicting.
Aim: We investigated whether FXIII Val34Leu polymorphism is potent enough to affect fibrin clot properties in patients with advanced coronary artery disease (CAD).
Methods: We studied 113 patients, aged 62.8 ± 6.1 years, who were scheduled for elective isolated coronary artery bypass grafting surgery (CABG). Patients were compared with 98 healthy age-matched controls. Ex vivo fibrin clot permeability and lysis time (t50%) were determined in citrated plasma.
Results: Patients scheduled for CABG had lower clot permeability (9.14 ± 1.64 vs. 10.02 ± 1.12 × 10-9 cm2; p = 0.0002) and longer t50% (8.45 ± 1.94 vs. 7.63 ± 1.24 min; p < 0.0001) than controls. The Leu34 carriers, i.e. 9 (8%) Leu34Leu homozygous and 23 (20%) Val34Leu heterozygous subjects, had lower permeability by 23% in the CAD group compared with 81 (72%) patients with Val34Val genotype. A similar intergroup difference was observed for t50% which was longer in Leu34 carriers (p < 0.0001). The FXIII Leu34 allele frequency in the control group was similar as well as the impact of Leu34 allele on fibrin properties. The effect of FXIII Leu34 allele on permeability and t50% was not affected by homocysteine, C-reactive protein and fibrinogen levels in CAD patients and controls.
Conclusions: Like in healthy subjects, in patients scheduled for CABG, the FXIII Leu34 allele is associated with decreased fibrin clot permeability and efficiency of lysis.
Get Citation

Keywords

factor XIII; fibrinolysis; coronary artery disease; polymorphism

About this article
Title

Original article
Factor XIII Val34Leu polymorphism as a modulator of fibrin clot permeability and resistance to lysis in patients with severe coronary artery disease

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 67, No 8 (2009)

Pages

947-955

Published online

2009-09-09

Bibliographic record

Kardiol Pol 2009;67(8):947-955.

Keywords

factor XIII
fibrinolysis
coronary artery disease
polymorphism

Authors

Ewa Stępień
Dariusz Plicner
Bogusław Kapelak
Ewa Wypasek
Jerzy Sadowski
Anetta Undas

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl